ABR-215062 Laquinimod

Laquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.

Properties:

Density: 1.395g/cm3

Boiling Point: 471.9ºC at 760mmHg

Flash Point: 239.2ºC

Refractive Index: 1.674

Vapor Pressure: 0mmHg at 25°C

Immunology & Inflammation related Inhibitors Related Prodcuts:

Pimecrolimus; Cyclosporin A; Bestatin; GI254023X; Bindarit; TAPI-1; Avadomide; Thymopentin; Pranlukast; VGX-1027; Y-320; Imiquimod; Levamisole hydrochloride; Halcinonide; Sodium gualenate; Aceclofenac; Fenoprofen calcium; Pidotimod; Etofenamate; Tenoxicam

[1]. Schulze-Topphoff, Ulf., et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012), 7(3), e33797.

[2]. Toubi E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. J Neuroimmunol. 2012 Oct 15;251(1-2):45-54.